Home > Insider Trading > Filing (0001209191-16-137322)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1673237	Julie Papanek	C/O Protagonist Therapeutics, Inc. 521 Cottonwood Drive, Suite 100 Milpitas CA 95035		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-08-16	1,869,922	$0.00	1,869,922	No	4	C	Indirect	By Canaan X L.P.
Common Stock	Acquisiton	2016-08-16	583,333	$12.00	2,453,255	No	4	P	Indirect	By Canaan X L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Canaan X L.P.
No	4	P	Indirect	By Canaan X L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2016-08-16	27,113,877	$0.00	1,869,922	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

The number of shares of common stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Preferred Stock converted into one share of common stock of the Issuer at the closing of the Issuer's initial public offering.
Each share of the Issuer's Series C Preferred Stock, which had no expiration date, automatically converted into the Issuer's common stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering, for no additional consideration.
These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The Reporting Person is a non-managing member of Canaan Partners X LLC, the general partner of the Canaan Fund. The Reporting Person does not have voting, investment or dispositive power over any of the shares directly held by the Canaan Fund and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.